Previous research has shown that blocking CDK activity could reduce inflammation activity in a lupus-prone mouse model, while inhibiting NFKB pathways reduced IFN expression in vitro, highlighting their potential role in treating persistent features in patients under remission [47, 48]. Here, IFNA1 is linked to systemic lupus erythematosus.